Skip to main content

Table 1 Aconitase immunoreactivity of BPH glandular epithelumversus adenocarcinomatous glands of prostate cancer tissue sections.

From: Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues

  TUMOR ACONITASE IMMUNOREACTIVITY ZIP1 IMMUNOREACTIVITY
CASE # GRADE BPH PCA BPH Malignant
1 3 +++ 8.9 ++ 6.4 ++ Negative
2 3 + 6.4 +++ 11.0 ++ +
3 1 + 6.2 + 7.0 + Negative
4 2 +++ 14.6 +++ 12.2 + Negative
5 2 ++ 12.6 + 14.2 Negative Negative
6 1 +++ 12.2 +++ 16.6 ++ Negative
7 2 ++ 10.0 +++ 15.6 + +
8 1 +++ 11.4 ++ 8.3 ++ +
9 1 + 7.5 +++ 18.0 ++ Negative
10 2 + 8.4 + 8.6 ++ Negative
11 1 + 12.6 ++ 11.8 ++ Negative
12 2 + 9.7 +++ 15.8 Negative Negative
13 1 +++ 13.7 +++ 14.2 ++ +
14 1 +++ 13.9 +++ 14.5 + Negative
15 1 + 7.6 + 10.2 + Negative
16 1 ++ 11.6 +++ 13.9 + Negative
17 1 ++ 14.2 +++ 16.3 ++ +
18 1 ++ 9.2 ++ 10.0 + Negative
19 1 +++ 12.0 ++ 10.9 + Negative
20 2 +++ 14.7 +++ 18.2 ++ +
21 1 +++ 14.1 +++ 17.6 Negative Negative
22 3 +++ 16.3 +++ 17.9 ------------- -------------
t-TEST- MEAN(SE)  
POSITIVITY 2.1(0.85) 2.4(0.94)** 1.68(0.23) 0.32(0.10)*
QUANTITATION 11.3(2.9) 13. 1(3.8)** ------------- -------------
  1. Scoring of immunoreactivity: Negative, no positive cells;
  2. score +, <10% positive cells; score ++, 10–50% positive cells;
  3. score +++, > 50% positive cells.
  4. Quantitation = Average number of well defined ACON IHC dots per cell.
  5. Mean Positivity = sum of +'s/22
  6. ZIP1 data taken from Franklin et al [14].
  7. BPH vs Malignant *P < 0.01; **no significant difference